Structure Therapeutics Inc. (GPCR) News
Follow Structure Therapeutics Inc. (GPCR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Structure Therapeutics Q3 Loss Widens on Higher R&D Costs
EQUITY | Nov 09, 2026, 09:21 PM UTC
M
Structure Therapeutics Reports $144.8 Million Q3 Net Loss and $1.2 Billion Cash
The company reported a third-quarter 2026 net loss of $144.8 million and $1.2 billion in cash, cash equivalents and short-term investments as of September 30. Research and development expenses rose to $134.6 million from
EQUITY | Nov 09, 2026, 09:18 PM UTC
L
Form SCHEDULE 13G/A Structure Therapeutics Filed by: FMR LLC
Filed on: November 5, 20
EQUITY | Nov 05, 2026, 06:27 PM UTC
M
VKTX, GPCR, ALT stocks jump after Novo Nordisk M&A signal
Novo Nordisk said it could pursue larger acquisitions while targeting more than five “multi-blockbuster” launches by 2030, lifting smaller obesity players: Viking Therapeutics gained nearly 4%, Structure Therapeutics ros
EQUITY | Sep 22, 2026, 05:29 AM UTC
L
Citizens maintains $110 per-share price target on Structure Therapeutics
Citizens maintained a $110.00-per-share price target for Structure Therapeutics.
EQUITY | Sep 09, 2026, 01:05 PM UTC
M
Structure Therapeutics posts positive early data for oral weight-loss program
Structure Therapeutics reported Phase 1/2a SAD results for ACCG-2671, an oral amylin receptor agonist, citing ~6-day half-life, no serious adverse events, and target engagement including up to 3.3% body weight loss.
EQUITY | Sep 08, 2026, 12:13 PM UTC
L
GPCR - Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Managem
GPCR - Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management
EQUITY | Sep 08, 2026, 12:02 PM UTC
L
Structure Therapeutics to participate in upcoming healthcare investor conferences
Structure Therapeutics Inc. said management will participate in three healthcare investor conferences, as outlined in its latest announcement.
EQUITY | Sep 03, 2026, 11:38 AM UTC
L
GPCR - Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
GPCR - Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
EQUITY | Sep 03, 2026, 11:30 AM UTC
H
GLP-1 Drugs Disrupt Food Chain
GLP-1 medications are changing consumer behavior, reducing food consumption and increasing demand for nutrient-dense products, affecting various industries including food, pharmaceuticals, and airlines.
EQUITY | Jun 22, 2026, 11:18 AM UTC